Presents SD-965 as an effective STAT3 degrader in cancer models, suggesting its therapeutic potential.
Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of novel STAT3 PROTAC degraders using high-affinity STAT3 ligands and cereblon ligands. Our study led to the discovery of SD-965 as a potent, selective, and efficacious STAT3 degrader. A single intravenous administration of SD-965 effectively induces rapid, complete, and durable depletion of STAT3 protein in mouse native and human xenograft tumor tissues with no depletion of other STAT proteins. SD-965 is capable of achieving tumor regression even with weekly administration in human leukemia and lymphoma xenograft models in mice without any signs of toxicity. SD-965 represents a promising STAT3 degrader for extensive evaluation for the treatment of human cancers and other human diseases.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: